New Delhi, June 12 -- Pharmaceutical companies in India are expected to grow steadily at a rate of approximately 10 per cent in FY26, driven by price increases and the launch of new products, according to a report by ICICI Securities.

The report noted that the revenue growth for the industry was mainly supported by the Rest of the World (RoW) markets.

It said "India biz is likely to grow at a steady pace of approx. 10 per cent in FY26, driven by price increases and new launches".

In contrast, the report stated that the core markets of the United States and India saw a slower pace of growth, recording 6.5 per cent and 10.2 per cent respectively.

The performance in the U.S. market remains uncertain, especially due to the looming price c...